New Weight-Loss Pill Approved by FDA
The Food and Drug Administration (FDA) has approved Eli Lilly’s new weight-loss pill, marking a significant development in the market for non-injectable GLP-1 weight-loss drugs. This approval provides consumers with an additional option in a rapidly growing industry.
Lilly will market its new medication under the brand name Foundayo. The once-daily prescription pill is intended for adults who have obesity or are overweight with weight-related medical conditions. Prior to this approval, Novo Nordisk’s Wegovy was the only FDA-approved GLP-1 pill available since December 2025.
Market Expansion and Consumer Options
The introduction of Foundayo introduces another choice for individuals seeking GLP-1-based weight-loss solutions. Both Lilly and Novo Nordisk are capitalizing on the trend of daily weight-loss pills, which appeal to consumers who prefer not to take injections or have been hesitant to use weight-loss medications.
For those without insurance coverage for weight-loss drugs, Foundayo is available at a cost of $149 for a one-month supply of the lowest dose, with higher doses starting at $299 per month. Individuals with insurance that covers weight-loss medications may benefit from a savings card, potentially reducing their monthly costs to as little as $25.
Clinical Trial Results and Side Effects
In clinical trials, participants who took the highest dose of Foundayo experienced an average weight loss of about 27 pounds, compared to just 2 pounds for those on a placebo. However, the medication can cause various side effects, including nausea, constipation, diarrhea, vomiting, indigestion, stomach pain, headaches, fatigue, burping, reflux disease, gas, and hair loss.
David Ricks, CEO of Eli Lilly, highlighted that fewer than 1 in 10 people who could benefit from a GLP-1 drug are currently using one. He stated that Foundayo aims to make weight-loss treatment more accessible for those living with obesity or related health complications.
Dan Skovronsky, Lilly’s chief scientific and product officer, emphasized that a pill form could help reduce the stigma associated with obesity and encourage more people to seek treatment. He noted that many adults already take oral medications for conditions like high blood pressure and cholesterol, making a pill a more approachable option.
Competition and Future Prospects
With the launch of Foundayo, Lilly is positioning itself to compete with Novo Nordisk’s popular weight-loss pill, Wegovy. Since its approval, Wegovy has seen a surge in demand, with over 600,000 prescriptions issued.
This competition mirrors the rivalry between injectable weight-loss drugs, such as Lilly’s Zepbound and Novo’s Wegovy, which have driven global demand for anti-obesity medications. Goldman Sachs predicts that global sales of these drugs could reach $105 billion by 2030.
However, health insurance companies have been slow to cover these medications. A survey by Mercer found that 49% of large employers covered GLP-1 medications for obesity in 2025, while another survey by KFF reported that 43% of larger employers paid for anti-obesity drugs.
Both companies have introduced discount programs for customers without insurance coverage. On March 31, Novo launched a subscription plan for Wegovy, offering discounts of nearly 30% through telehealth partners such as Ro, Weight Watchers, and LifeMD. Monthly costs for Wegovy range from $249 to $289, depending on the subscription length.
Conclusion
The approval of Foundayo represents a pivotal moment in the weight-loss medication market. As companies continue to innovate and expand their offerings, the landscape for managing obesity and related health conditions is evolving rapidly. With increased accessibility and competitive pricing, more individuals may soon find themselves with viable options to achieve their health goals.
